The Microbiome in COPD: Emerging Potential for Microbiome-Targeted Interventions.

Area of Science:

• Microbiology
• Pulmonology
• Gastroenterology

Background:

• Chronic obstructive pulmonary disease (COPD) management involves inhaled therapies, including corticosteroids, and antibiotics for exacerbations.
• Corticosteroid use can increase bronchial microbial load and pathogenic bacteria, particularly in patients with low eosinophil counts.
• Antibiotic use during exacerbations reduces microbial diversity, a persistent change in frequent exacerbators.

Purpose of the Study:

• To explore interventions for the respiratory microbiome in COPD to preserve native flora and improve disease prognosis.
• To evaluate the impact of minimizing inhaled corticosteroids and antibiotic use on microbial diversity and patient outcomes.
• To investigate the potential of oral antiseptics, probiotics, prebiotics, and dietary modifications on the respiratory and gut microbiomes in COPD.

Main Methods:

• Review of existing literature on COPD treatments and their effects on the respiratory and gut microbiomes.
• Analysis of how inhaled corticosteroids and antibiotics influence microbial load, diversity, and specific taxa.
• Exploration of emerging strategies like oral antiseptics, probiotics, prebiotics, and high-fiber diets.
• Consideration of the gut-lung axis in modulating respiratory inflammation and hyperreactivity.

Main Results:

• High-diversity bronchial microbiomes are associated with lower exacerbation rates and improved survival.
• Limiting antibiotic use to essential cases may enhance respiratory microbiome diversity, quality of life, and survival.
• Oral antiseptics have shown improvements in quality of life linked to bronchial microbiome changes.
• Probiotics, prebiotics, and high-fiber diets may influence the gut microbiome, potentially reducing lung inflammation.

Conclusions:

• Interventions should focus on preserving the respiratory microbiome in COPD, selecting patients carefully for corticosteroid and antibiotic therapies.
• Maintaining a microbiome closer to that of healthy individuals may promote respiratory health.
• The gut-lung axis offers a potential pathway for therapeutic intervention through dietary and microbial modulation.
• Further clinical validation is required to identify patient subgroups who would most benefit from microbiome-targeted therapies for COPD.